Thin Reinforced Ion-Exchange Membranes Containing Fluorine Moiety for All-Vanadium Redox Flow Battery.

In this work, we developed pore-filled ion-exchange membranes (PFIEMs) fabricated for the application to an all-vanadium redox flow battery (VRFB) by filling a hydrocarbon-based ionomer containing a fluorine moiety into the pores of a porous polyethylene (PE) substrate having excellent physical and chemical stabilities. The prepared PFIEMs were shown to possess superior tensile strength (i.e., 136.6 MPa for anion-exchange membrane; 129.9 MPa for cation-exchange membrane) and lower electrical resistance compared with commercial membranes by employing a thin porous PE substrate as a reinforcing material. In addition, by introducing a fluorine moiety into the filling ionomer along with the use of the porous PE substrate, the oxidation stability of the PFIEMs could be greatly improved, and the permeability of vanadium ions could also be significantly reduced. As a result of the evaluation of the charge-discharge performance in the VRFB, it was revealed that the higher the fluorine content in the PFIEMs was, the higher the current efficiency was. Moreover, the voltage efficiency of the PFIEMs was shown to be higher than those of the commercial membranes due to the lower electrical resistance. Consequently, both of the pore-filled anion- and cation-exchange membranes showed superior charge-discharge performances in the VRFB compared with those of hydrocarbon-based commercial membranes.

Antagonistic interaction between central glucagon-like Peptide-1 and oxytocin on diet-induced obesity mice.

Glucagon-like peptide-1 (GLP-1), whose agonists are widely prescribed, is a peptide proven effective in reducing obesity. Similarly, oxytocin (OXT) is a peptide known to increase satiety and help reduce body weight. In the present study, we aimed to examine the metabolic effects of co-administration of GLP-1 and OXT in diet-induced obesity (DIO) mice to elucidate their functions and interactions in the central nervous system. To this end, 40 DIO mice were subjected to stereotaxic surgery for the installation of an osmotic minipump and intracerebroventricular administration of GLP-1, OXT, or both. Initially, it was anticipated that co-administration of these anorexigenic peptides would be as effective as, if not more than, either GLP-1 or OXT alone in providing metabolic benefits to the obese mice. Interestingly, co-administration of OXT and GLP-1 offset the reductions in body weight and food intake promoted by either peptide alone. Co-administration also negated the decrease in fat and increase in lean mass produced by either peptide alone. Moreover, co-administration showed an equivalent calorimetric benefit as either peptide alone. Therefore, these results suggest antagonistic, rather than synergistic or additive, effects of centrally administered GLP-1 and OXT that attenuate the metabolic benefits of either peptide.